Martina Novotna, MD, Moses Rodriguez, MD, and Orhun H. Kantarci, MD
October 2015—Current immunomodulatory treatments for MS are not reliable to prevent long-term disability, but future agents focusing on remyelination and axonal and neuronal repair could reverse this course.
Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.